Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has received an average recommendation of “Buy” from the seven ratings firms that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $24.64.

AMPH has been the topic of several research reports. Wells Fargo & Co set a $29.00 price target on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 6th. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research note on Wednesday, July 10th. Finally, TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, August 7th.

In other Amphastar Pharmaceuticals news, insider Jason B. Shandell sold 6,615 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $20.31, for a total transaction of $134,350.65. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Yakob Liawatidewi sold 1,515 shares of the stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $21.24, for a total transaction of $32,178.60. Following the sale, the senior vice president now owns 36,670 shares in the company, valued at $778,870.80. The disclosure for this sale can be found here. Insiders sold 39,454 shares of company stock worth $838,842 over the last 90 days. 30.80% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its stake in Amphastar Pharmaceuticals by 1.5% during the second quarter. BlackRock Inc. now owns 5,927,141 shares of the company’s stock worth $125,124,000 after buying an additional 87,107 shares in the last quarter. Vanguard Group Inc. grew its stake in Amphastar Pharmaceuticals by 2.5% during the second quarter. Vanguard Group Inc. now owns 2,381,761 shares of the company’s stock worth $50,279,000 after buying an additional 57,349 shares in the last quarter. Federated Investors Inc. PA grew its stake in Amphastar Pharmaceuticals by 8.7% during the first quarter. Federated Investors Inc. PA now owns 1,472,931 shares of the company’s stock worth $30,092,000 after buying an additional 117,480 shares in the last quarter. Renaissance Technologies LLC grew its stake in Amphastar Pharmaceuticals by 33.2% during the second quarter. Renaissance Technologies LLC now owns 588,000 shares of the company’s stock worth $12,413,000 after buying an additional 146,400 shares in the last quarter. Finally, Nuveen Asset Management LLC acquired a new stake in Amphastar Pharmaceuticals during the second quarter worth about $12,134,000. Hedge funds and other institutional investors own 47.26% of the company’s stock.

Shares of AMPH traded down $0.90 during trading hours on Thursday, hitting $21.25. The company had a trading volume of 60,978 shares, compared to its average volume of 194,327. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of 101.19 and a beta of 1.17. The business has a fifty day moving average of $21.12 and a 200-day moving average of $21.15. Amphastar Pharmaceuticals has a 12 month low of $17.71 and a 12 month high of $25.43. The company has a quick ratio of 1.83, a current ratio of 2.81 and a debt-to-equity ratio of 0.13.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.05. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. The business had revenue of $79.00 million for the quarter, compared to the consensus estimate of $78.90 million. During the same period in the prior year, the company posted $0.03 earnings per share. Amphastar Pharmaceuticals’s revenue was up 11.3% compared to the same quarter last year. On average, equities analysts expect that Amphastar Pharmaceuticals will post 0.15 EPS for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Story: Earnings Reports

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.